Serum CXCL6 as a biomarker for diagnosing and predicting progression of interstitial lung disease in ANCA-associated vasculitis.

ABSTRACT:

Objective

To investigate serum CXCL6 as a biomarker at diagnosis and predict progression of interstitial lung disease (ILD) in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Methods

Baseline serum CXCL6 levels were measured in 292 AAV patients and 82 healthy controls. Correlations with clinical parameters and disease activity were examined. To assess its role in ILD progression, the association between baseline CXCL6 levels and ILD progression during follow up was evaluated using univariable and multivariable analyses.

Results

Serum CXCL6 levels were significantly elevated in AAV patients compared to healthy controls, and were markedly higher in those with ILD than without ILD. The frequency of ILD in AAV patients with high serum

SUBMITTER: Li W 

PROVIDER: S-EPMC12860018 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature